Cargando…
Anti-IL-17A antibody-associated de novo vitiligo: Case report and review of literature
Interleukin (IL)-17 inhibitor is a biological therapy approved for moderate to severe psoriasis and psoriatic arthritis. The common adverse events of IL-17 inhibitor include injection site reaction, infections, nasopharyngitis, and headache. However, vitiligo associated with the use of IL-17 inhibit...
| Autores principales: | , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Frontiers Media S.A.
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9889818/ https://www.ncbi.nlm.nih.gov/pubmed/36741377 http://dx.doi.org/10.3389/fimmu.2022.1077681 |